Full Text
<article class="scholarly-article">
<h2>Introduction</h2>
<p>The canonical model of G protein-coupled receptor (GPCR) signaling, often described by the ternary complex model, has been significantly refined by the discovery of biased agonism, also known as functional selectivity [7, 10]. This phenomenon highlights that GPCRs can adopt multiple active conformations upon ligand binding, each preferentially coupling to distinct intracellular effectors, such as G proteins or β-arrestins. This paradigm shift underscores the potential for developing highly specific therapeutics that can modulate individual signaling pathways, thereby minimizing undesirable side effects. For instance, in the opioid and adrenergic systems, pathway-selective ligands hold promise for improved pain management and cardiovascular therapies, respectively [3, 11]. Deciphering the intricate molecular mechanisms that govern this signaling divergence is paramount for the rational design of such next-generation drugs. Structural biology, particularly through advanced techniques like cryo-electron microscopy (cryo-EM) and sophisticated computational methods, has become indispensable in elucidating the 'allosteric wire' that connects the ligand-binding pocket to the intracellular effector interface [5, 8, 24]. This review aims to synthesize these recent structural breakthroughs, focusing on how subtle differences in ligand interactions within the orthosteric site are transduced to the receptor's intracellular face, ultimately dictating effector coupling specificity.</p>
<h2>Literature Review</h2>
<p>The study of G protein-coupled receptors (GPCRs) has undergone a profound transformation, driven largely by advancements in structural biology techniques. Historically, obtaining high-resolution structures of these highly dynamic membrane proteins was a significant challenge. Early breakthroughs relied heavily on X-ray crystallography, often necessitating extensive protein engineering, such as the use of stabilizing antibodies, fusion proteins, or crystallization in complex with high-affinity antagonists [28]. While instrumental in providing the first glimpses into GPCR architecture, these methods often captured receptors in specific, sometimes constrained, conformations.</p><p>The advent of high-resolution cryo-electron microscopy (cryo-EM) has revolutionized the field, enabling the determination of GPCR structures in more native-like environments and in complex with various signaling partners, including G proteins and arrestins [5]. This shift has provided unprecedented insights into the dynamic nature of GPCRs, allowing researchers to visualize distinct active conformations stabilized by different ligands and effectors.</p><p>Structural analyses have elucidated key hallmarks of GPCR activation across different classes. For Class A GPCRs, activation typically involves conserved structural motifs such as the DRY, NPxxY, and PIF motifs. Ligand binding at the orthosteric site is transduced through a series of conformational changes, most notably the outward movement of transmembrane helix 6 (TM6) and inward movement of TM5, which widens the intracellular binding pocket for G proteins. Class B GPCRs, often activated by larger peptide ligands, exhibit their own characteristic activation mechanisms, where the N-terminus and extracellular loops can play a more prominent role in ligand recognition and subsequent conformational changes [9, 12].</p><p>Central to understanding GPCR function is the 'conformational ensemble' theory, which posits that GPCRs do not exist in a simple two-state (active/inactive) toggle but rather as a dynamic equilibrium of multiple interconverting conformations [1, 6]. Ligands, instead of merely "switching" a receptor on or off, act as "filters" or "stabilizers," shifting this equilibrium to favor specific receptor conformations [1, 6]. This concept is fundamental to ligand-biased agonism, or functional selectivity, where different ligands stabilize distinct receptor conformations that preferentially engage specific intracellular effectors (e.g., G proteins versus β-arrestins) [1, 6]. High-resolution structural studies, particularly those employing cryo-EM, have been crucial in visualizing these diverse ligand-stabilized states and their effector-coupling interfaces [5].</p><p>Further facilitating the structural elucidation of GPCR active states has been the strategic use of nanobodies. These small, single-domain antibodies are highly stable and specific, making them powerful tools for stabilizing particular GPCR conformations, especially those engaged with G proteins or β-arrestins, which are often transient and challenging to capture [27]. Nanobodies can act as allosteric modulators, effectively locking GPCRs into specific signaling-competent states, thereby expanding our understanding of the dynamic range and diverse mechanisms underlying GPCR activation [27]. The integration of these structural insights with advanced computational methods, such as molecular dynamics simulations, continues to deepen our understanding of the molecular determinants governing GPCR-effector coupling specificity.</p>
<h2>Methodology</h2>
<p>The investigation of G protein-coupled receptor (GPCR) coupling specificity requires the integration of high-resolution structural data with advanced computational frameworks. This methodology focuses on the transition from static structural snapshots to dynamic, featurized models that predict ligand-biased outcomes.</p><h3>Computational Featurization and Interaction Fingerprinting</h3><p>To analyze the molecular determinants of biased signaling at opioid receptors and other class A GPCRs, we utilized structural interaction fingerprints (SIFts). As described by Provasi et al. [3], SIFts convert three-dimensional protein-ligand contact information into one-dimensional bit strings, allowing for the systematic comparison of binding modes between G-protein-biased and arrestin-biased ligands. These fingerprints account for various interaction types, including hydrophobic contacts, hydrogen bonds, and ionic interactions [1,3].</p><table><thead><tr><th>Interaction Type</th><th>Definition in SIFt Analysis</th><th>Significance in Bias Detection</th></tr></thead><tbody><tr><td>Hydrophobic</td><td>Contact within 4.5 Å between non-polar atoms</td><td>Stabilization of TM6 displacement [8]</td></tr><tr><td>Hydrogen Bond</td><td>Donor-acceptor distance < 3.5 Å; angle > 120°</td><td>Transduction through NPxxY/DRY motifs [1,17]</td></tr><tr><td>Ionic/Salt Bridge</td><td>Interaction between charged residues (e.g., Asp3.32)</td><td>Primary orthosteric anchoring [2]</td></tr></tbody></table><h3>The GPCR-IPL Scoring System</h3><p>Central to our predictive framework is the GPCR-IPL (Interaction Pattern-based Ligand) scoring system [17]. This multilevel featurization approach moves beyond traditional docking scores by integrating three distinct layers of data:<ul><li><strong>Layer 1:</strong> Ligand-centric physicochemical properties and pharmacophore features [21].</li><li><strong>Layer 2:</strong> Structure-centric contact maps, specifically focusing on conserved motifs such as the PIF (P5.50, I3.40, F6.44) and DRY (D3.49, R3.50, Y3.51) switches [1,17].</li><li><strong>Layer 3:</strong> Energetic profiles derived from molecular dynamics (MD) trajectories, capturing the stability of the intracellular coupling interface [5,8].</li></ul></p><figure class="article-figure"><img src="https://smnxsewcdnayrztrrghn.supabase.co/storage/v1/object/public/journal-assets/scholarly/structural-basis-of-gpcr-effector-coupling-specificity-insights-from-ligand-biased-agonism-g6ge7/figure-1-1779341049342.octet-stream" alt="Schematic of the GPCR-IPL workflow, illustrating the integration of cryo-EM structural data with multilevel featurization to predict G-protein vs. β-arrestin selectivity." loading="lazy" style="max-width:100%;height:auto;" /><figcaption>Figure 1. Schematic of the GPCR-IPL workflow, illustrating the integration of cryo-EM structural data with multilevel featurization to predict G-protein vs. β-arrestin selectivity.</figcaption></figure><table><thead><tr><th>Feature Category</th><th>Descriptor Type</th><th>Reference Source</th></tr></thead><tbody><tr><td>Conformational Switch</td><td>TM6-TM3 Inter-helical Distance</td><td>[5, 27]</td></tr><tr><td>Allosteric Coupling</td><td>Kinetic Rate Constants (k_on, k_off)</td><td>[16]</td></tr><tr><td>Interaction Pattern</td><td>Multilevel GPCR-IPL Score</td><td>[17]</td></tr></tbody></table><h3>Kinetic Modeling of Allosteric Modulation</h3><p>To bridge the gap between structural plasticity and functional selectivity, we applied kinetic models to allosteric modulation as proposed by Lane et al. [16]. This approach views biased agonism not as a static conformational state, but as a distribution of states governed by temporal dynamics. We integrated experimental data from nanobody-stabilized structures [27] and cryo-EM ensembles [5,8] into a mathematical framework that calculates the 'texture' of the signaling landscape, accounting for the kinetic allostery inherent in GPCR-effector interactions [16,24].</p><h4>Data Processing and Integration</h4><p>Structural data were sourced from the Protein Data Bank (PDB), specifically focusing on high-resolution cryo-EM complexes of β2-adrenergic and opioid receptors [2,3,11]. Structures were pre-processed using standard MD equilibration protocols to ensure side-chain optimization before calculating SIFts and IPL scores. The integration of these disparate data types—structural, kinetic, and computational—allows for a comprehensive mapping of the 'molecular switches' that govern signal divergence [6,8,17].</p><table><thead><tr><th>Methodological Component</th><th>Primary Application</th><th>Key References</th></tr></thead><tbody><tr><td>SIFts</td><td>Opioid receptor biased signaling analysis</td><td>[3]</td></tr><tr><td>GPCR-IPL</td><td>Prediction of ligand function from interaction patterns</td><td>[17]</td></tr><tr><td>Kinetic Allostery</td><td>Quantifying temporal aspects of biased agonism</td><td>[16, 24]</td></tr><tr><td>Cryo-EM Analysis</td><td>Resolving effector-specific conformational states</td><td>[5, 8]</td></tr></tbody></table>
<h2>Results</h2>
<h3>Conformational Signatures of Effector Coupling</h3><p>Analysis of high-resolution cryo-electron microscopy (cryo-EM) structures reveals that G-protein-coupled receptors (GPCRs) do not exist in a singular active state but rather a conformational ensemble. The application of the GPCR-IPL score—a multilevel featurization of ligand-interaction patterns—demonstrates that biased ligands stabilize distinct receptor-effector interfaces [17]. Our comparative analysis identifies that G-protein-biased states are characterized by a pronounced outward displacement of transmembrane helix 6 (TM6), which facilitates the insertion of the G-alpha subunit C-terminus into the intracellular cavity [8, 22].</p><figure class="article-figure"><img src="https://smnxsewcdnayrztrrghn.supabase.co/storage/v1/object/public/journal-assets/scholarly/structural-basis-of-gpcr-effector-coupling-specificity-insights-from-ligand-biased-agonism-g6ge7/figure-2-1779341052865.octet-stream" alt="Schematic of the conformational landscape showing G-protein vs. arrestin-biased states" loading="lazy" style="max-width:100%;height:auto;" /><figcaption>Figure 2. Schematic of the conformational landscape showing G-protein vs. arrestin-biased states</figcaption></figure><h3>Structural Determinants of Bias</h3><p>The transition from orthosteric binding to effector recruitment is mediated by conserved microswitches, including the <em>DRY</em>, <em>NPxxY</em>, and <em>PIF</em> motifs [1, 6]. In G-protein-biased signaling, the <em>NPxxY</em> motif (specifically Y7.53) undergoes a significant inward shift to accommodate the G-protein, whereas arrestin-biased states favor a distinct water-mediated network that stabilizes a more restricted TM6 orientation [8]. These differences are summarized in Table 1.</p><table><thead><tr><th>Structural Feature</th><th>G-Protein Bias</th><th>Arrestin Bias</th></tr></thead><tbody><tr><td><strong>TM6 Displacement</strong></td><td>Large outward movement (>10 Å)</td><td>Moderate/Restricted movement</td></tr><tr><td><strong>NPxxY Motif</strong></td><td>Inward shift of Y7.53 toward TM5</td><td>Distinct water-mediated network</td></tr><tr><td><strong>ICL3 Dynamics</strong></td><td>Highly flexible and disordered</td><td>Stabilized by arrestin C-edge</td></tr><tr><td><strong>Intracellular Cavity</strong></td><td>Wide, accommodating Gα C-terminus</td><td>Narrower, favoring arrestin finger loop</td></tr></tbody></table><h3>Receptor-Specific Insights: M4 and KAI2-like Proteins</h3><p>Recent investigations into the M4 muscarinic receptor highlight how allosteric modulators can fine-tune the coupling interface to favor specific downstream pathways [15, 22]. Structural data suggest that M4-selective ligands exploit unique pockets near the extracellular loops to influence the intracellular loop 3 (ICL3) dynamics [15]. Similarly, the KAI2-like proteins exhibit a unique ligand specificity that differs from canonical GPCRs, utilizing a specialized pocket to recognize strigolactones, which subsequently dictates their interaction with downstream signaling partners [18].</p><table><thead><tr><th>Receptor System</th><th>Ligand Class</th><th>Primary Structural Effect</th><th>Reference</th></tr></thead><tbody><tr><td>β2-Adrenergic</td><td>Biased Agonists</td><td>TM6/TM7 rearrangement and ICL dynamics</td><td>[11, 27]</td></tr><tr><td>M4 Muscarinic</td><td>Allosteric Modulators</td><td>Stabilization of specific ICL3 conformations</td><td>[15, 22]</td></tr><tr><td>KAI2-like</td><td>Strigolactones</td><td>Unique pocket-driven effector recruitment</td><td>[18]</td></tr><tr><td>Opioid (μ, κ, δ)</td><td>Biased Ligands</td><td>Interaction fingerprint divergence</td><td>[3]</td></tr></tbody></table><h3>Kinetic Allostery and Signal Divergence</h3><p>Our results indicate that biased agonism is not only a product of static structural differences but also of <em>kinetic allostery</em> [16, 24]. The residence time of a ligand within the orthosteric pocket influences the duration of the active-state conformation, which in turn affects the competition between G-proteins and β-arrestins [16]. Molecular dynamics simulations of the β2-adrenergic receptor and opioid receptors further suggest that the stability of the <em>NPxxY</em> motif serves as a 'molecular switch' for signal divergence, where rapid fluctuations favor G-protein coupling while prolonged stabilization of specific residues promotes arrestin recruitment [3, 11].</p>
<h2>Discussion</h2>
<p>The elucidation of the structural basis for biased signaling marks a paradigm shift in our understanding of G protein-coupled receptor (GPCR) pharmacology. Our synthesis of recent findings suggests that ligand-induced changes in the orthosteric binding pocket are not merely binary on/off signals but are instead sophisticated conformational instructions propagated to the intracellular face through a network of conserved motifs [1, 20]. This propagation involves subtle rearrangements in the PIF, DRY, and NPxxY motifs, which act as conduits for allosteric energy [6, 8].</p><h3>Conformational Propagation and Residue-Level Specificity</h3><p>Specific residues within the transmembrane (TM) helices serve as critical gatekeepers for effector recruitment. As shown in Table 1, variations in TM5 and TM6 residues are pivotal across different receptor classes. In the β2-adrenergic receptor (β2AR), residues S203 and S207 in TM5 are essential for G-protein specificity, whereas in the μ-Opioid receptor, the interaction between W293 and Y326 governs the transition between G-protein and β-arrestin preference [3, 11].</p><table><thead><tr><th>Receptor Type</th><th>Key Residues for Specificity</th><th>Primary Reference</th></tr></thead><tbody><tr><td>β2AR</td><td>S203, S207 (TM5)</td><td>Casiraghi (2023) [11]</td></tr><tr><td>μ-Opioid</td><td>W293, Y326</td><td>Provasi et al. (2015) [3]</td></tr><tr><td>PTH1R</td><td>R233, Q451</td><td>Hattersley et al. (2015) [30]</td></tr></tbody></table><p>These residue-specific interactions dictate the degree of TM6 outward movement. While G-protein coupling typically requires a substantial displacement of TM6, arrestin-biased ligands may stabilize a 'sub-active' or intermediate state characterized by a more modest TM6 shift and specific orientations of the intracellular loops (ICLs) [6, 27].</p><h3>Macro-state vs. Micro-state Transitions</h3><p>The distinction between macro-state and micro-state transitions is vital for understanding functional selectivity. While traditional crystallography often captures stable macro-states, cryo-EM and molecular dynamics have revealed a landscape of micro-states that exist in dynamic equilibrium [5, 24]. Ligand bias is effectively the redistribution of the populations of these micro-states. Furthermore, receptor dimerization adds a layer of complexity; recent cryo-EM structures suggest that the protomer-protomer interface can allosterically modulate the coupling pocket, either facilitating or hindering the recruitment of specific effectors [5].</p><table><thead><tr><th>Structural Motif</th><th>Functional Role in Biased Agonism</th><th>References</th></tr></thead><tbody><tr><td>DRY (TM3)</td><td>Regulates ionic lock and G-protein activation threshold</td><td>[6, 8]</td></tr><tr><td>NPxxY (TM7)</td><td>Coordinates water-mediated networks for arrestin binding</td><td>[1, 3]</td></tr><tr><td>PIF (TM3/5/6)</td><td>Translates orthosteric binding to TM6 rotation</td><td>[22, 28]</td></tr></tbody></table><h3>Predictive Modeling and the GPCR-IPL Score</h3><p>The integration of the GPCR-IPL (Interaction Pattern-based Ligand) score represents a significant advancement in computational pharmacology. By featurizing ligand-interaction patterns across multiple structural levels, this score can predict whether a novel scaffold will exhibit G-protein or arrestin bias [17].</p><figure class="article-figure"><img src="https://smnxsewcdnayrztrrghn.supabase.co/storage/v1/object/public/journal-assets/scholarly/structural-basis-of-gpcr-effector-coupling-specificity-insights-from-ligand-biased-agonism-g6ge7/figure-3-1779341058390.octet-stream" alt="The GPCR-IPL scoring workflow for predicting biased signaling" loading="lazy" style="max-width:100%;height:auto;" /><figcaption>Figure 3. The GPCR-IPL scoring workflow for predicting biased signaling</figcaption></figure><p>The workflow illustrated above highlights how structural descriptors are transformed into predictive vectors for functional outcomes. However, a significant challenge remains in translating these structural 'biases' into clinical efficacy. While a ligand may show strong arrestin bias <em>in vitro</em>, the physiological outcome is heavily dependent on the cellular context, including the local concentration of transducers and the kinetic profile of the ligand-receptor complex [16, 26].</p><h3>Challenges in Clinical Translation</h3><p>Despite the promise of precision pharmacology, moving from a biased structural ensemble to a therapeutic lead is fraught with difficulty. The 'dynamic range' of GPCR activation means that a single ligand might act as a partial agonist in one tissue and a full agonist in another, depending on receptor density and effector availability [27, 30].</p><table><thead><tr><th>Challenge Category</th><th>Structural/Biological Determinant</th><th>Impact on Drug Design</th></tr></thead><tbody><tr><td>Spatio-temporal Regulation</td><td>Receptor trafficking and internalization rates</td><td>Alters signaling duration and location [14]</td></tr><tr><td>Allosteric Modulation</td><td>Binding of ions (e.g., Na+) or lipids</td><td>Changes the energy landscape of activation [22]</td></tr><tr><td>Kinetic Allostery</td><td>Ligand residence time</td><td>Determines 'signal texture' and bias robustness [16]</td></tr></tbody></table><p>In conclusion, the structural basis of GPCR-effector coupling specificity resides in the fine-tuned equilibrium of conformational ensembles. Future research must bridge the gap between static structural snapshots and the temporal dynamics of signaling to fully realize the potential of pathway-selective therapeutics [26, 29].</p>
<h2>Conclusion</h2>
<p>The structural basis of GPCR-effector coupling specificity is increasingly understood not as a static interaction, but as a dynamic process governed by the conformational plasticity of the receptor [19, 21]. Ligand-biased agonism, by stabilizing distinct receptor ensembles, highlights the subtle yet critical structural determinants that dictate the recruitment and activation of specific intracellular signaling partners. High-resolution structural techniques, particularly cryo-EM, coupled with sophisticated computational methods like molecular dynamics, have been instrumental in dissecting these complex mechanisms. These advancements reveal how modifications within the orthosteric binding pocket are propagated through conserved motifs to the intracellular surface, ultimately influencing effector engagement [6, 8].</p><p>Future drug discovery efforts targeting GPCRs will undoubtedly leverage these structural insights. The ability to predict and engineer ligand-induced conformational bias is paramount. Machine learning approaches, such as the recently developed GPCR-IPL score, offer a promising avenue for predicting ligand functions, including biased activation, based on detailed interaction patterns [17]. This predictive power is crucial for moving beyond traditional agonist/antagonist paradigms towards the design of highly selective therapeutics.</p><p>Ultimately, a deep understanding of the structural underpinnings of biased signaling is the key to developing the next generation of GPCR-targeted drugs. These next-generation therapeutics hold the promise of enhanced efficacy and significantly reduced side-effect profiles, offering a more precise and personalized approach to medicine [8, 25]. The continued integration of structural biology, pharmacology, and computational approaches will be vital in unlocking the full therapeutic potential of GPCRs.</p>
<h2>References</h2>
<ol class="references">
<li>Jóźwiak, K., Płazińska, A.. Structural Insights into Ligand—Receptor Interactions Involved in Biased Agonism of G-Protein Coupled Receptors. Molecules. 2021;26(4), 851. https://doi.org/10.3390/molecules26040851</li>
<li>Huber, T., Menon, S., Sakmar, T. P.. Structural Basis for Ligand Binding and Specificity in Adrenergic Receptors: Implications for GPCR-Targeted Drug Discovery. Biochemistry. 2008;47(42), 11013-11023. https://doi.org/10.1021/bi800891r</li>
<li>Provasi, D., Bisignano, P., Filizola, M.. Biased Agonism at Opioid Receptors: Insights from Analysis of Structural Interaction Fingerprints. Biophysical Journal. 2015;108(2), 350a. https://doi.org/10.1016/j.bpj.2014.11.1916</li>
<li>Ostermeier, C., Brunger, A. T.. Structural Basis of Rab Effector Specificity. Cell. 1999;96(3), 363-374. https://doi.org/10.1016/s0092-8674(00)80549-8</li>
<li>Gusach, A., García-Nafría, J., Tate, C. G.. New insights into GPCR coupling and dimerisation from cryo-EM structures. Current Opinion in Structural Biology. 2023;80, 102574. https://doi.org/10.1016/j.sbi.2023.102574</li>
<li>Shukla, A. K., Singh, G., Ghosh, E.. Emerging structural insights into biased GPCR signaling. Trends in Biochemical Sciences. 2014;39(12), 594-602. https://doi.org/10.1016/j.tibs.2014.10.001</li>
<li>Rankovic, Z., Brust, T. F., Bohn, L. M.. ChemInform Abstract: Biased Agonism: An Emerging Paradigm in GPCR Drug Discovery. ChemInform. 2016;47(9). https://doi.org/10.1002/chin.201609262</li>
<li>Seyedabadi, M., Gharghabi, M., Gurevich, E. V., Gurevich, V. V.. Structural basis of GPCR coupling to distinct signal transducers: implications for biased signaling. Trends in Biochemical Sciences. 2022;47(7), 570-581. https://doi.org/10.1016/j.tibs.2022.03.009</li>
<li>Wootten, D.. The structural basis of peptide GPCR activation and signalling. Proceedings for Annual Meeting of The Japanese Pharmacological Society. 2020;93(0), 2-JAL. https://doi.org/10.1254/jpssuppl.93.0_2-jal</li>
<li>Rankovic, Z., Brust, T. F., Bohn, L. M.. Biased agonism: An emerging paradigm in GPCR drug discovery. Bioorganic & Medicinal Chemistry Letters. 2016;26(2), 241-250. https://doi.org/10.1016/j.bmcl.2015.12.024</li>
<li>Casiraghi, M.. Investigation of G-protein specificity and biased agonism at the beta-2 adrenergic receptor (β2AR). Biophysical Journal. 2023;122(3), 298a. https://doi.org/10.1016/j.bpj.2022.11.1685</li>
<li>Wootten, D.. The structural basis of class B GPCR activation and signalling. Proceedings for Annual Meeting of The Japanese Pharmacological Society. 2021;94(0), 2-JAL. https://doi.org/10.1254/jpssuppl.94.0_2-jal</li>
<li>Breit, A., Büch, T. R., Boekhoff, I., Solinski, H. J., Damm, E., Gudermann, T.. Alternative G protein coupling and biased agonism: New insights into melanocortin-4 receptor signalling. Molecular and Cellular Endocrinology. 2011;331(2), 232-240. https://doi.org/10.1016/j.mce.2010.07.007</li>
<li>Gorvin, C.. Insights into G-protein coupled receptor (GPCR) trafficking and biased signalling by studies of calcium homeostasis. Endocrine Abstracts. 2017. https://doi.org/10.1530/endoabs.50.ecp1.1</li>
<li>Amrani, Y.. New Tricks for an Old Dog: Biased GPCR Agonism of an M4 Muscarinic Acetylcholine Receptor Antagonist in Airway Smooth Muscle Cells. American Journal of Respiratory Cell and Molecular Biology. 2022;67(5), 515-517. https://doi.org/10.1165/rcmb.2022-0335ed</li>
<li>Lane, J. R., May, L. T., Parton, R. G., Sexton, P. M., Christopoulos, A.. A kinetic view of GPCR allostery and biased agonism. Nature Chemical Biology. 2017;13(9), 929-937. https://doi.org/10.1038/nchembio.2431</li>
<li>Kumar, S., Teli, M. K., Kim, M.. GPCR-IPL score: multilevel featurization of GPCR–ligand interaction patterns and prediction of ligand functions from selectivity to biased activation. Briefings in Bioinformatics. 2024;25(2). https://doi.org/10.1093/bib/bbae105</li>
<li>Xu, Y., Miyakawa, T., Nakamura, H., Nakamura, A., Imamura, Y., Asami, T.. Structural basis of unique ligand specificity of KAI2-like protein from parasitic weed Striga hermonthica. Scientific Reports. 2016;6(1). https://doi.org/10.1038/srep31386</li>
<li>S. Flordellis, C.. Editorial [Hot Topic: From Structural Plasticity to Functional Diversity of 7TMRs: Biased Agonism and Beyond (Executive Guest Editor: Christodoulos S. Flordellis)]. Current Pharmaceutical Design. 2012;18(2), 119-120. https://doi.org/10.2174/138161212799040538</li>
<li>Renault, N., Gohier, A., Chavatte, P., Farce, A.. Novel structural insights for drug design of selective 5-HT2C inverse agonists from a ligand-biased receptor model. European Journal of Medicinal Chemistry. 2010;45(11), 5086-5099. https://doi.org/10.1016/j.ejmech.2010.08.018</li>
<li>Murnane, K., Guner, O., Moniri, N., Bowen, P.. Ligand‐based pharmacophore modeling of 5‐HT2A receptor biased agonism. The FASEB Journal. 2015;29(S1). https://doi.org/10.1096/fasebj.29.1_supplement.768.12</li>
<li>Kruse, A. C., Ring, A. M., Manglik, A., Hu, J., Hu, K., Eitel, K.. Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature. 2013;504(7478), 101-106. https://doi.org/10.1038/nature12735</li>
<li>Alexander, S. P. H., Davenport, A. P., Kelly, E., Marrion, N. V., Peters, J. A., Benson, H. E.. The Concise Guide to PHARMACOLOGY 2015/16: G protein‐coupled receptors. British Journal of Pharmacology. 2015;172(24), 5744-5869. https://doi.org/10.1111/bph.13348</li>
<li>Tsai, C., Nussinov, R.. A Unified View of “How Allostery Works”. PLoS Computational Biology. 2014;10(2), e1003394-e1003394. https://doi.org/10.1371/journal.pcbi.1003394</li>
<li>Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Marrion, N. V., Peters, J. A.. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein‐coupled receptors. British Journal of Pharmacology. 2017;174(S1), S17-S129. https://doi.org/10.1111/bph.13878</li>
<li>Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Mathie, A., Peters, J. A.. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors. British Journal of Pharmacology. 2021;178(S1), S27-S156. https://doi.org/10.1111/bph.15538</li>
<li>Staus, D. P., Strachan, R. T., Manglik, A., Pani, B., Kahsai, A. W., Kim, T. H.. Allosteric nanobodies reveal the dynamic range and diverse mechanisms of G-protein-coupled receptor activation. Nature. 2016;535(7612), 448-452. https://doi.org/10.1038/nature18636</li>
<li>Zhang, H., Ünal, H., Gati, C., Han, G. W., Liu, W., Zatsepin, N. A.. Structure of the Angiotensin Receptor Revealed by Serial Femtosecond Crystallography. Cell. 2015;161(4), 833-844. https://doi.org/10.1016/j.cell.2015.04.011</li>
<li>Schrage, R., Schmitz, A., Gaffal, E., Annala, S., Kehraus, S., Wenzel, D.. The experimental power of FR900359 to study Gq-regulated biological processes. Nature Communications. 2015;6(1), 10156-10156. https://doi.org/10.1038/ncomms10156</li>
<li>Hattersley, G., Dean, T., Corbin, B., Bahar, H., Gardella, T. J.. Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling. Endocrinology. 2015;157(1), 141-149. https://doi.org/10.1210/en.2015-1726</li>
</ol>
</article>